TY - JOUR T1 - Evasion of neutralizing antibodies by Omicron sublineage BA.2.75 JF - bioRxiv DO - 10.1101/2022.07.19.500716 SP - 2022.07.19.500716 AU - Daniel J. Sheward AU - Changil Kim AU - Julian Fischbach AU - Sandra Muschiol AU - Roy A. Ehling AU - Niklas K. Björkström AU - Gunilla B. Karlsson Hedestam AU - Sai T. Reddy AU - Jan Albert AU - Thomas P. Peacock AU - Ben Murrell Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/07/20/2022.07.19.500716.abstract N2 - Towards the end of 2021, SARS-CoV-2 vaccine effectiveness was threatened by the emergence of the Omicron clade (B.1.1.529), with more than 30 mutations in spike. Recently, several sublineages of Omicron, including BA.2.12.1, BA.4, and BA.5, have demonstrated even greater immune evasion, and are driving waves of infections across the globe.One emerging sublineage, BA.2.75, is increasing in frequency in India and has been detected in at least 15 countries as of 19 July 2022. Relative to BA.2, BA.2.75 carries nine additional mutations in spike. Here we report the sensitivity of the BA.2.75 spike to neutralization by a panel of clinically-relevant and pre-clinical monoclonal antibodies, as well as by serum from blood donated in Stockholm, Sweden, before and after the BA.1/BA.2 infection wave.BA.2.75 does not show greater immune evasion than the currently-dominating BA.5 in our set of serum samples, and exhibits moderate susceptibility to tixagevimab and cilgavimab that form a widely used monoclonal antibody cocktail (Evusheld).Competing Interest StatementSTR is a cofounder of and held shares in deepCDR Biologics, which has been acquired by Alloy Therapeutics. All other authors declare no competing interests. ER -